Bristol John W & Co. Inc. NY Sells 65,595 Shares of Celgene Co. (NASDAQ:CELG)

Bristol John W & Co. Inc. NY cut its holdings in shares of Celgene Co. (NASDAQ:CELG) by 11.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 527,462 shares of the biopharmaceutical company’s stock after selling 65,595 shares during the quarter. Celgene accounts for 2.0% of Bristol John W & Co. Inc. NY’s investment portfolio, making the stock its 26th largest position. Bristol John W & Co. Inc. NY owned approximately 0.07% of Celgene worth $68,501,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Stifel Financial Corp increased its position in shares of Celgene by 5.8% in the 2nd quarter. Stifel Financial Corp now owns 1,285,937 shares of the biopharmaceutical company’s stock valued at $166,962,000 after purchasing an additional 69,977 shares during the last quarter. Numeric Investors LLC increased its position in shares of Celgene by 169.9% in the 2nd quarter. Numeric Investors LLC now owns 267,700 shares of the biopharmaceutical company’s stock valued at $34,766,000 after purchasing an additional 168,500 shares during the last quarter. Brandywine Global Investment Management LLC increased its position in shares of Celgene by 2.8% in the 2nd quarter. Brandywine Global Investment Management LLC now owns 382,913 shares of the biopharmaceutical company’s stock valued at $49,729,000 after purchasing an additional 10,332 shares during the last quarter. Voya Investment Management LLC increased its position in shares of Celgene by 3.8% in the 2nd quarter. Voya Investment Management LLC now owns 2,403,020 shares of the biopharmaceutical company’s stock valued at $312,080,000 after purchasing an additional 87,393 shares during the last quarter. Finally, Carmignac Gestion increased its position in shares of Celgene by 0.4% in the 2nd quarter. Carmignac Gestion now owns 7,595,821 shares of the biopharmaceutical company’s stock valued at $986,469,000 after purchasing an additional 28,000 shares during the last quarter. Institutional investors own 80.16% of the company’s stock.

In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by company insiders.

A number of research analysts recently commented on CELG shares. William Blair reaffirmed an “outperform” rating on shares of Celgene in a research report on Friday, October 20th. BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. Leerink Swann reaffirmed a “buy” rating and issued a $156.00 target price on shares of Celgene in a research report on Friday, October 20th. Deutsche Bank started coverage on shares of Celgene in a research report on Tuesday, December 12th. They issued a “hold” rating and a $114.00 target price on the stock. Finally, Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $133.00 target price on shares of Celgene in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $136.21.

Celgene Co. (NASDAQ:CELG) traded up $1.17 during mid-day trading on Friday, hitting $109.41. 9,719,225 shares of the stock traded hands, compared to its average volume of 5,339,085. Celgene Co. has a one year low of $94.55 and a one year high of $147.17. The firm has a market cap of $86,140.36, a PE ratio of 17.10, a PEG ratio of 0.84 and a beta of 1.78. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the business earned $1.58 EPS. The business’s revenue was up 10.2% on a year-over-year basis. equities research analysts forecast that Celgene Co. will post 6.68 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Bristol John W & Co. Inc. NY Sells 65,595 Shares of Celgene Co. (NASDAQ:CELG)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/17/bristol-john-w-co-inc-ny-has-68-50-million-holdings-in-celgene-corporation-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply